Competitive Comparison of SELLAS Life Sciences Group's Profitability Rank
For the Biotechnology subindustry, SELLAS Life Sciences Group's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Profitability Rank distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Profitability Rank falls into.
SELLAS Life Sciences Group Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
SELLAS Life Sciences Group has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
SELLAS Life Sciences Group's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
SELLAS Life Sciences Group has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
SELLAS Life Sciences Group (SELLAS Life Sciences Group) Business Description
Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Executives
| Angelos M. Stergiou |
director, officer: President and CEO |
C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, SUITE 380, SAN RAMON CA 94583 |
| Barbara A Wood |
officer: EVP, Gen. Counsel, Corp. Sec. |
58 S SERVICE RD, MELVILLE NY 11747 |
| John Thomas Burns |
officer: VP, Finance & Corp Controller |
16760 SW UPPER BOONES FERRY RD, SUITE 101, PORTLAND X1 97224 |
| Katherine Bach Kalin |
director |
3201 CARNEGIE AVENUE, CLEVELAND OH 44115 |
| Robert Francomano |
officer: Chief Commercial Officer |
C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 11TH FLOOR, NEW YORK NY 10022 |
| Nicholas J. Sarlis |
officer: Chief Medical Officer and SVP |
C/O SELLAS LIFE SCIENCES GROUP, INC., 2000 CROW CANYON PLACE, STE. 380, SAN RAMON CA 94583 |
| Stephen F Ghiglieri |
director |
C/O NEUROGESX INC., 981 INDUSTRIAL ROAD SUITE F, SAN CARLOS CA 94070 |
| Jane Wasman |
director |
C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| David A Scheinberg |
director |
325 CENTRAL PARK W, APT 38, NEW YORK NY 10025 |
| Van Nostrand Robert L |
director |
C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
| John Varian |
director |
ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely Ii Fund` |
10 percent owner |
C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
| Eqc Private Markets Sac Fund Ltd-eqc Biotech Sely I Fund |
10 percent owner |
C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
| Equilibria Capital Management Ltd |
10 percent owner |
O'HARA HOUSE, ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
| Eqc Private Markets Ii Sac Fund Ltd-eqc Biotech Sely Iii Fund |
10 percent owner |
C/O EQUILIBRIA CAPITAL MANAGEMENT LTD., ONE BERMUDIANA ROAD, HAMILTON D0 HM08 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SLS has been successfully added to your